Hubei Jumpcan Pharmaceutical (600566.SH) subsidiary obtains drug registration certificate.
Jichuan Pharmaceutical (600566.SH) announced that recently, its wholly-owned subsidiary Jichuan Pharmaceutical Group Co., Ltd. (referred to as "Jichuan Limited") received the drug registration certificates for Pediatric Laxative Granules and Mesalazine Sustained-Release Granules approved and issued by the National Medical Products Administration.
Hubei Jumpcan Pharmaceutical (600566.SH) announced that its wholly-owned subsidiary Hubei Jumpcan Pharmaceutical Group Co., Ltd. (referred to as "Jumpcan Limited") has recently received the Drug Registration Certificates for Pediatric Constipation Granules and Mesalazine Sustained-Release Granules approved by the National Medical Products Administration.
The acquisition of the Drug Registration Certificates for Pediatric Constipation Granules and Mesalazine Sustained-Release Granules represents a further complement to the company's products, enriching its product line, and is expected to play a positive role in the company's future development.
Related Articles
Jiangsu Jiejie Microelectronics (300623.SZ) plans to launch a restricted stock incentive plan in 2026.
Huadong Medicine (000963.SZ) subsidiary medical devices have obtained EU MDR CE certification.
CASIN Real Estate Development Group (000838.SZ) signed the "Restructuring Investment Agreement" with pre-restructuring investors, and the stock has resumed trading.
Jiangsu Jiejie Microelectronics (300623.SZ) plans to launch a restricted stock incentive plan in 2026.
Huadong Medicine (000963.SZ) subsidiary medical devices have obtained EU MDR CE certification.
CASIN Real Estate Development Group (000838.SZ) signed the "Restructuring Investment Agreement" with pre-restructuring investors, and the stock has resumed trading.
RECOMMEND
